Cargando…

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities

Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Koehm, Michaela, Behrens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514622/
https://www.ncbi.nlm.nih.gov/pubmed/37734874
http://dx.doi.org/10.1136/rmdopen-2023-003166
_version_ 1785108764220719104
author Koehm, Michaela
Behrens, Frank
author_facet Koehm, Michaela
Behrens, Frank
author_sort Koehm, Michaela
collection PubMed
description Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15 501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease.
format Online
Article
Text
id pubmed-10514622
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105146222023-09-23 Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities Koehm, Michaela Behrens, Frank RMD Open Psoriatic Arthritis Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15 501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease. BMJ Publishing Group 2023-09-21 /pmc/articles/PMC10514622/ /pubmed/37734874 http://dx.doi.org/10.1136/rmdopen-2023-003166 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Psoriatic Arthritis
Koehm, Michaela
Behrens, Frank
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title_full Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title_fullStr Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title_full_unstemmed Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title_short Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
title_sort association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
topic Psoriatic Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514622/
https://www.ncbi.nlm.nih.gov/pubmed/37734874
http://dx.doi.org/10.1136/rmdopen-2023-003166
work_keys_str_mv AT koehmmichaela associationbetweenbiologicalimmunotherapyforpsoriasisandtimetoincidentinflammatoryarthritislimitationsandopportunities
AT behrensfrank associationbetweenbiologicalimmunotherapyforpsoriasisandtimetoincidentinflammatoryarthritislimitationsandopportunities